GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » Forward Dividend Yield %

Oramed Pharmaceuticals (XTAE:ORMP) Forward Dividend Yield % : 0.00% (As of May. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals Forward Dividend Yield %?

As of today (2024-05-26), the Forward Annual Dividend Yield of Oramed Pharmaceuticals is 0.00%.

As of today (2024-05-26), the Trailing Annual Dividend Yield of Oramed Pharmaceuticals is 0.00%.

XTAE:ORMP's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful Forward Dividend Yield % only.

Oramed Pharmaceuticals's Dividends per Share for the three months ended in Mar. 2024 was ₪0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Oramed Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, Oramed Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Forward Dividend Yield % falls into.



Oramed Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Oramed Pharmaceuticals  (XTAE:ORMP) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Oramed Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals (XTAE:ORMP) Business Description

Comparable Companies
Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.